Compare SHIP & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHIP | FENC |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 370.7M | 366.8M |
| IPO Year | 2008 | 2010 |
| Metric | SHIP | FENC |
|---|---|---|
| Price | $15.99 | $10.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $23.25 | $17.67 |
| AVG Volume (30 Days) | ★ 302.1K | 104.8K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | $30.86 | $62.55 |
| Revenue Next Year | N/A | $42.10 |
| P/E Ratio | ★ $13.34 | $180.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.17 | $5.65 |
| 52 Week High | $19.22 | $13.25 |
| Indicator | SHIP | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 43.35 | 55.09 |
| Support Level | $15.35 | $9.87 |
| Resistance Level | $16.77 | $11.29 |
| Average True Range (ATR) | 0.53 | 0.50 |
| MACD | 0.01 | 0.09 |
| Stochastic Oscillator | 35.32 | 71.01 |
Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through a modern fleet of Capesize vessels. It generates a majority of its revenue from the vessels. The company's fleet of vessels includes Blueship, Meiship, Kaizenship, Iconship, Titanship, Flagship, Paroship, Worldship, Hellasship, Partnership, Championship, Patriotship, Dukeship, Honorship, Fellowship, Knightship, Lordship, Premiership, Squireship, and Friendship.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.